-
Something wrong with this record ?
The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance
P. Dundr, B. Bazalová, M. Bártů, T. Bosse, J. Drozenová, P. Fabian, O. Fadare, J. Hausnerová, R. Jakša, J. Laco, SF. Lax, R. Matěj, WG. McCluggage, G. Méhes, R. Michálková, K. Němejcová, N. Singh, S. Stolnicu, P. Škapa, M. Švajdler, I. Stružinská
Language English Country Germany
Document type Journal Article
Grant support
AZV NV19-03-00007
Ministerstvo Zdravotnictví Ceské Republiky
MH CZ DRO-VFN 64165
Ministerstvo Zdravotnictví Ceské Republiky
UNCE204065
Univerzita Karlova v Praze
EF16_013/0001674
European Regional Development Fund
BBMRI_CZ LM2018125
European Regional Development Fund
NLK
ProQuest Central
from 2003-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2003-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2003-01-01 to 1 year ago
- MeSH
- Adenocarcinoma * diagnosis MeSH
- Diagnosis, Differential MeSH
- Gastrointestinal Neoplasms * diagnosis MeSH
- Immunohistochemistry MeSH
- Keratin-17 MeSH
- Colorectal Neoplasms * diagnosis MeSH
- Humans MeSH
- Biomarkers, Tumor analysis MeSH
- Pancreatic Neoplasms * diagnosis MeSH
- Ovarian Neoplasms * pathology MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.
Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Pathology Belfast Health and Social Care Trust Belfast UK
Department of Pathology Faculty of Medicine University of Debrecen 4032 Debrecen Hungary
Department of Pathology General Hospital Graz 2 Graz Austria
Department of Pathology Leiden University Medical Center Leiden Netherlands
Department of Pathology University of California San Diego San Diego CA USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025130
- 003
- CZ-PrNML
- 005
- 20221031100346.0
- 007
- ta
- 008
- 221017s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00428-022-03338-z $2 doi
- 035 __
- $a (PubMed)35554675
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz $1 https://orcid.org/http://orcid.org/0000000289406124
- 245 14
- $a The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance / $c P. Dundr, B. Bazalová, M. Bártů, T. Bosse, J. Drozenová, P. Fabian, O. Fadare, J. Hausnerová, R. Jakša, J. Laco, SF. Lax, R. Matěj, WG. McCluggage, G. Méhes, R. Michálková, K. Němejcová, N. Singh, S. Stolnicu, P. Škapa, M. Švajdler, I. Stružinská
- 520 9_
- $a We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.
- 650 12
- $a adenokarcinom $x diagnóza $7 D000230
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 12
- $a kolorektální nádory $x diagnóza $7 D015179
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a gastrointestinální nádory $x diagnóza $7 D005770
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a keratin-17 $7 D053537
- 650 12
- $a nádory vaječníků $x patologie $7 D010051
- 650 12
- $a nádory slinivky břišní $x diagnóza $7 D010190
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bazalová, Barbora $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Bosse, Tjalling $u Department of Pathology, Leiden University Medical Center, Leiden, Netherlands
- 700 1_
- $a Drozenová, Jana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic
- 700 1_
- $a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Fadare, Oluwole $u Department of Pathology, University of California San Diego, San Diego, CA, USA
- 700 1_
- $a Hausnerová, Jitka $u Department of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Jakša, Radek $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Lax, Sigurd F $u Department of Pathology, General Hospital Graz II, Graz, Austria $u Johannes Kepler University Linz, Linz, Austria
- 700 1_
- $a Matěj, Radoslav $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a McCluggage, W Glenn $u Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK
- 700 1_
- $a Méhes, Gábor $u Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary
- 700 1_
- $a Michálková, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Singh, Naveena $u Department of Cellular Pathology, Barts Health NHS Trust, and Blizard Institute of Core Pathology, Queen Mary University of London, London, UK
- 700 1_
- $a Stolnicu, Simona $u Department of Pathology, Pharmacy, Sciences and Technology of Targu Mures, University of Medicine, Targu Mures, Romania
- 700 1_
- $a Škapa, Petr $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Švajdler, Marián $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 773 0_
- $w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 481, č. 2 (2022), s. 201-212
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35554675 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100344 $b ABA008
- 999 __
- $a ok $b bmc $g 1854702 $s 1176420
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 481 $c 2 $d 201-212 $e 20220513 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
- GRA __
- $a AZV NV19-03-00007 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a MH CZ DRO-VFN 64165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a UNCE204065 $p Univerzita Karlova v Praze
- GRA __
- $a EF16_013/0001674 $p European Regional Development Fund
- GRA __
- $a BBMRI_CZ LM2018125 $p European Regional Development Fund
- LZP __
- $a Pubmed-20221017
